Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK.
Nature. 2012 May 16;486(7403):400-4. doi: 10.1038/nature11017.
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer clonal selective advantage on cancer cells and are causally implicated in oncogenesis, and the remainder are passenger mutations. The driver mutations and mutational processes operative in breast cancer have not yet been comprehensively explored. Here we examine the genomes of 100 tumours for somatic copy number changes and mutations in the coding exons of protein-coding genes. The number of somatic mutations varied markedly between individual tumours. We found strong correlations between mutation number, age at which cancer was diagnosed and cancer histological grade, and observed multiple mutational signatures, including one present in about ten per cent of tumours characterized by numerous mutations of cytosine at TpC dinucleotides. Driver mutations were identified in several new cancer genes including AKT2, ARID1B, CASP8, CDKN1B, MAP3K1, MAP3K13, NCOR1, SMARCD1 and TBX3. Among the 100 tumours, we found driver mutations in at least 40 cancer genes and 73 different combinations of mutated cancer genes. The results highlight the substantial genetic diversity underlying this common disease.
所有癌症的基因组都携带有体细胞突变。其中一部分被称为驱动突变,它们赋予癌细胞克隆选择优势,并与肿瘤发生有因果关系,其余的则是乘客突变。乳腺癌中的驱动突变和突变过程尚未得到全面探索。在这里,我们研究了 100 个肿瘤的体细胞拷贝数变化和编码蛋白基因外显子的突变。个体肿瘤之间的体细胞突变数量差异显著。我们发现突变数量与癌症诊断时的年龄和癌症组织学分级之间存在很强的相关性,并且观察到多个突变特征,包括在大约 10%的肿瘤中存在的特征,这些肿瘤具有大量 TpC 二核苷酸处胞嘧啶的突变。在包括 AKT2、ARID1B、CASP8、CDKN1B、MAP3K1、MAP3K13、NCOR1、SMARCD1 和 TBX3 在内的几个新癌症基因中发现了驱动突变。在这 100 个肿瘤中,我们发现了至少 40 个癌症基因和 73 种不同的突变癌症基因组合中的驱动突变。这些结果突出了这种常见疾病背后的巨大遗传多样性。